The "2016 Chinese guideline for the management of dyslipidemia in adults" (the new Guide for short) released by Chinese Journal of Cardiology is based on the 2007 "Guide for Dyslipidemia Prevention in Chinese Adults" (the 2007 Hyperlipidemia Guide for short) and is the result of a year's effort and work by a team of specialists. 1 The public release of the 2007 Hyperlipidemia Guide has had a positive effect on control and management of hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD). In the past decade, there has been a paradigm shift in international and domestic research and the viewpoints in this field; thus, a new guide for dyslipidemia is imperative.
The group of specialists who have formulated the guides, from the 1997 "Recommendations for Dyslipidemia Prevention" to the first dyslipidemia guideline in China, until the formulation of this new Guide, have adhered to three principles. First, they used international guides as a reference with an emphasis on the data and evidence from Chinese research, without blind obedience to foreign guides. Second, they adhered to the public welfare and scientific nature of the guide, with no interference of various business interests. Third, they embody authority, as the formulation process for the guide brought together specialists in the field; scientific democracy was fully upheld, evidence was thoroughly collected and evaluated, and authorization was granted by the Disease Prevention and Control Bureau of the National Health and Family Planning Commission, China.
New situations and challenges faced during formulation of the new Guide
The 2007 Hyperlipidemia Guide was primarily based
on results from Chinese epidemiological studies conducted over many years, with the highlight being based on the risk stratification for cardiovascular diseases (including stroke) formulated using our own data; owing to the high incidence of ischemic stroke in China, the weight of hypertension in the risk stratification was increased. One example is the growing number of the much-hyped small-scale, short follow-up, exploratory studies in which observations act as substitutes for endpoints. These one-sided exaggerated claims of multiple effects (such as anti-inflammatory effects) outside the primary role of statins in lowering the cholesterol suggest the sequential use of 80 mg atorvastatin during the perioperative period of percutaneous coronary intervention (PCI) and acute coronary syndrome (ACS). More seriously, this misconception is already widely accepted in several countrylevel hospitals.
The Chinese new Guide is clear, raises the banners of public welfare and science, adheres to the characteristic evidence from Chinese studies without following the ACC/AHA, and strictly rejects and resists intervention related to business interests. 
